Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Share-based Compensation (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Share-based Compensation readings, the most recent being $193000.0 for Q4 2017.

  • On a quarterly basis, Share-based Compensation rose 565.52% to $193000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $579000.0, a 78.47% decrease, with the full-year FY2025 number at $10.5 million, down 20.36% from a year prior.
  • Share-based Compensation hit $193000.0 in Q4 2017 for Eledon Pharmaceuticals, up from $150000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.2 million in Q3 2014 to a low of $29000.0 in Q4 2016.
  • Median Share-based Compensation over the past 5 years was $419500.0 (2014), compared with a mean of $468055.6.
  • Biggest five-year swings in Share-based Compensation: surged 2408.51% in 2014 and later crashed 96.62% in 2016.
  • Eledon Pharmaceuticals' Share-based Compensation stood at $101000.0 in 2013, then soared by 483.17% to $589000.0 in 2014, then surged by 45.5% to $857000.0 in 2015, then crashed by 96.62% to $29000.0 in 2016, then surged by 565.52% to $193000.0 in 2017.
  • The last three reported values for Share-based Compensation were $193000.0 (Q4 2017), $150000.0 (Q3 2017), and $130000.0 (Q2 2017) per Business Quant data.